CD38 and Miyoshi myopathy: For MM, FT576 integrates a BCMA CAR with CD38 KO, hnCD16, and IL-15 signaling, protecting against MM progression in preclinical studies (Dhakal et al., 2022; Goodridge et al., 2021).